Biogen Idec And Abbott Announce Positive Top-Line Results
Links shared publicly online about this topic.
- 85total visits
Biogen Idec And Abbott Announce Positive Top-Line Results
View full resource at abbott.com
Tags: Multiple Sclerosis, Biogen Idec
Most Recently Shared on August 9, 2011 at 1:59 pm By:
Biogen Idec & Abbott announce topline Ph 2b results from daclizumab HYP trial 4 relapse-remitting multiple sclerosis - http://ow.ly/5YIqm
Biogen Idec and Abbott Announce Positive Top-Line Results from the First Registrational Trial for Daclizumab HYP in Relapsing-Remitting Multiple Sclerosis - Drugs.com MedNews
drugs.com — “SELECT Study Demonstrates Significant Reductions in Annualized Relapse Rate and Meets Key Secondary Endpoints Full Data to Be Presented at an Upcoming Medical M” View full resource at drugs.com
Most Recently Shared on August 9, 2011 at 5:31 pm By:
Drugs and Devices OW OW Health
Biogen Idec and Abbott Announce Positive Top-Line Results from the First Registrational Trial for Daclizum... http://bit.ly/oBxHfP #drug
Biogen Idec Announces Positive Top-Line Results From The First Phase 3 Trial Investigating Oral BG-12 (DIMETHYL FUMARATE) In Multiple Sclerosis
medicalnewstoday.com — “Biogen Idec (NASDAQ: BIIB) announced today positive top-line results from DEFINE, the first of two pivotal Phase 3 clinical trials designed to evaluate the investigational oral compound BG-12 (dim” View full resource at medicalnewstoday.com
Most Recently Shared on April 12, 2011 at 3:05 pm By:
Biogen Idec Announces Positive Top-Line Results From The First Phase 3 Trial Investigating Oral BG-12 (DIMETHYL FUMARA... http://mnt.to/3TwZ
Biogen Idec Announces Positive Top-Line Results from the First Phase 3 Trial Investigating Oral BG-12 (DIMETHYL FUMARATE) in Multiple Sclerosis - Drugs.com MedNews
drugs.com — “- DEFINE Study Achieves Primary and All Secondary Endpoints for Both Study Doses - - Full Data to Be Presented at a Future Medical Meeting - Apr 11, 2011 - Biog” View full resource at drugs.com
Most Recently Shared on April 11, 2011 at 12:04 pm By:
Drugs and Devices OW OW Health
Biogen Idec Announces Positive Top-Line Results from the First Phase 3 Trial Investigating Oral BG-12 (DIM... http://bit.ly/ebzoNt #drug
Biogen Idec Announces Positive Top-Line Results from the First Phase 3 Trial Investigating Oral BG-12 (DIMETHYL FUMARATE) in Multiple Sclerosis
vancouversun.com — “Biogen Idec Announces Positive Top-Line Results from the First Phase 3 Trial Investigating Oral BG-12” View full resource at vancouversun.com
Most Recently Shared on April 11, 2011 at 11:23 am By:
John Carroll Health Communicator
Biogen's MS drug hits primary, all secondary endpoints in 1st of two Ph3s. Here's the PR: http://bit.ly/eTG42m
Advertisement
